Latest news with #GlobalClinicalTrialsReview
Yahoo
17-07-2025
- Health
- Yahoo
Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
The "Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2025" report provides a comprehensive insight into worldwide OCD clinical trials. It covers trial numbers, average enrollment, regional data, and sponsor types, enhanced by the proprietary Pharma database. Ideal for strategic decision-making and identifying competitive opportunities. Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The "Obsessive-Compulsive Disorder - Global Clinical Trials Review, 2025" clinical trials has been added to offering. The clinical trial report provides an overview of Obsessive-Compulsive Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Obsessive-Compulsive Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Scope The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to Buy Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Report Guidance The analyst Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Countries Contributing to Clinical Trials in Middle East and Africa Top Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Obsessive-Compulsive Disorder to Central Nervous System Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Obsessive-Compulsive Disorder to Central Nervous System Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Obsessive-Compulsive Disorder Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profile Snapshots Appendix Competitive Landscape Roche Holding AG Pfizer Inc Viatris Inc The Lundbeck Foundation Torrent Investments Pvt Ltd Syneos Health Inc AbbVie Inc AstraZeneca Plc Sandoz Group AG Byondis BV For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Neuropathic Pain (Neuralgia) Global Clinical Trials Market Review 2025: Explore Trial Numbers, Enrollment Data, Prominent Drugs, and Regional Insights
Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Neuropathic Pain (Neuralgia) - Global Clinical Trials Review, 2025" has been added to offering. The comprehensive report offers an in-depth analysis of the ongoing clinical trials for Neuropathic Pain. It encompasses key data about trial numbers, average enrollment figures, and provides a detailed snapshot of clinical trials across various regions, including the G7 and E7 countries. The report categorizes trials based on region, trial phase, status, endpoint status, and sponsor type, providing a granular view of the clinical trial landscape. This report is instrumental for stakeholders aiming to understand the progress and scope of Neuropathic Pain trials globally. It lists significant drugs involved in active trials and utilizes the Pharma - Clinical Trials database, aggregated from over 80 clinical trial registries, academic conferences, and industry journals worldwide. As this database is subject to periodic updates through a dynamic process, it remains a reliable source for current data. The report is a valuable tool for enhancing strategic decision-making processes, allowing stakeholders to craft effective counterstrategies for a competitive edge in the market. Prospective buyers should note that certain sections of the report are subject to modification based on data availability and relevance. Scope Provides a global snapshot of the clinical trials landscape. Offers top-level data categorized by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and Endpoint Status. Lists trials alongside their titles, phases, and current status, spotlighting involved companies. Includes information on terminated, suspended, and withdrawn trials with reasoning. Analyzes enrollment trends over the past five years. Updates with the latest industry news from the past three months. Reasons to Buy Aids in crafting effective business strategies concerning investment. Identifies strategic locations for clinical trials, optimizing time and cost. Provides high-level analysis of the Global Clinical Trials Market, revealing key business opportunities. Supports understanding of trial numbers and enrollment trends globally. Offers insights into trial success rates by comparing terminated, suspended, and withdrawn trials with completed ones. Facilitates global, regional, and country-level assessments of clinical trials. Key Topics Covered: Report Guidance Clinical Trials by Region Clinical Trials by Country and Contribution Asia-Pacific Europe North America Middle East and Africa Central and South America Clinical Trials by G7 and E7 Countries Proportion to Central Nervous System Clinical Trials By Phase By Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Neuropathic Pain Therapeutics Prominent Drugs Latest Clinical Trials News on Neuropathic Pain Clinical Trial Profile Snapshots A selection of companies mentioned in this report includes, but is not limited to: Pfizer Inc Eli Lilly and Co AbbVie Inc GSK plc Viatris Inc Teva Pharmaceutical Industries Ltd Thermo Fisher Scientific Inc Johnson & Johnson AstraZeneca Plc Dr. Reddy's Laboratories Ltd For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Global Clinical Trials Market Review 2025
Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Global Clinical Trials Review, 2025" clinical trials has been added to report provides top line data relating to the clinical trials on Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to Buy Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Report Guidance The analyst Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Countries Contributing to Clinical Trials in Middle East and Africa Top Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) to Central Nervous System Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) to Central Nervous System Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profile Snapshots Appendix Company Profiles Teva Pharmaceutical Industries Ltd The Lundbeck Foundation Alterity Therapeutics Ltd ICON Plc Pfizer Inc AstraZeneca Plc Corestemchemon Inc Modag GmbH Theravance Biopharma Inc Thermo Fisher Scientific Inc For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
21-05-2025
- Health
- Yahoo
Chemotherapy-Induced Diarrhea (CID) Global (G7 & E7) Clinical Trials Market Review 2025
Explore the "Chemotherapy-Induced Diarrhea (CID) - Global Clinical Trials Review, 2025" report for vital insights into CID clinical trials worldwide. Discover top-line data, enrollment trends, and prominent drugs in progress, gathered from over 80 registries. Optimize strategies with this comprehensive market analysis. Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "Chemotherapy-Induced Diarrhea (CID) - Global Clinical Trials Review, 2025" has been added to offering. This report offers a comprehensive overview of the clinical trial landscape concerning CID. This specialized report focuses on providing crucial top-line data related to various CID clinical trials conducted worldwide, including trial numbers and average enrollment within leading countries. This in-depth review highlights the distribution of clinical trials by region, including G7 and E7 countries, and further classifies them by trial phase, status, end-point status, and sponsor type. Additionally, the report identifies key drugs involved in ongoing trials, presenting a clearer understanding of existing efforts to address CID. Generated from the proprietary Pharma - Clinical trials database, the report integrates insights from over 80 diverse clinical trial registries, conferences, journals, and news sources globally. The database is subject to regular, dynamic updates to ensure the reliability of the data. Designed to enhance strategic decision-making, this report equips stakeholders with the necessary insights to develop effective counter-strategies for competitive advantage. Note that certain sections may be modified subject to data availability and relevance for the specified disease. Scope Provides a snapshot of the global clinical trials landscape, detailing top-level data by region, country (G7 & E7), trial status, phase, sponsor type, and endpoint status. Reviews leading companies and lists all associated trials, including trial title, phase, and current status. Includes data on uncompleted trials, such as those terminated, suspended, or withdrawn, with clear explanations for these outcomes. Analyzes enrollment trends over the past five years, delivering a view of the evolving landscape. Presents the latest news over the past three months to ensure users remain informed on recent developments. Reasons to Buy Assists in formulating strategic investment decisions. Identifies strategic locations for clinical trials, optimizing resources and timing. Offers comprehensive analysis of the Global Clinical Trials Market, aiding in the identification of business opportunities. Facilitates understanding of trials count and enrollment trends, enriching strategic planning in the global therapeutics market. Provides comparative analysis of completed vs. uncompleted trials to evaluate success rates. Supports clinical trial assessments for indications at global, regional, and country levels. Key Topics Covered: Report Guidance The analyst Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Countries Contributing to Clinical Trials Asia-Pacific Europe North America Central and South America Clinical Trials by G7 Countries Proportion of CID to Toxicology Clinical Trials By Phase By Trial Status Clinical Trials by E7 Countries Proportion of CID to Toxicology Clinical Trials By Phase By Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in CID Therapeutics Clinical Trials Prominent Drugs Clinical Trial Profile Snapshots A selection of companies mentioned in this report includes, but is not limited to: 3B Future Holding SA GenesisCare Clinical CRO Pty Ltd Guangzhou Zhiyi Biotechnology Co Ltd Jaguar Health Inc Novartis AG Usynova Pharmaceuticals Ltd AGI Therapeutics Research Ltd CD Pharma India Pvt Ltd Celerion Inc Clearstone Holdings International Ltd For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
Atopic Dermatitis (Atopic Eczema) Global Clinical Trials Review 2025
This comprehensive report offers an overview of clinical trials, featuring data by region, country, phase, and sponsor type. Unlock competitive advantages with detailed analysis of ongoing trials and enrollment trends. Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2025" has been added to offering. The report delivers a comprehensive insight into the current landscape of clinical trials focused on Atopic Dermatitis (Atopic Eczema) worldwide. Leveraging data from the proprietary Pharma - Clinical trials database, the report encapsulates a broad spectrum of clinical trial information, presenting crucial statistics such as trial numbers and average enrollment across leading countries globally. This robust database aggregates information from over 80 diverse sources including clinical trial registries, conferences, journals, and news outlets, ensuring a meticulously updated repository of data. The report's extensive coverage includes detailed insights broken down by region and country (G7 & E7), trial phase, trial status, endpoints, and sponsor type. It highlights active trials and the significant drugs that are currently under investigation, aligning strategic interests with ongoing developments in the field of Atopic Dermatitis (Atopic Eczema). Benefits of engaging with this report extend to enhancing decision-making capabilities, crafting strategic responses, and securing a competitive market advantage. Although some sections may be adapted based on data availability and relevance, the offering continues to provide an indispensable tool for stakeholders aiming to navigate the clinical trials landscape effectively. Scope: Presents a snapshot of the global clinical trials environment. Delivers top-level data related to clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status. Evaluates leading companies and lists trials (title, phase, and status) associated with them. Documents all unaccomplished trials (terminated, suspended, and withdrawn), including reasons for their cessation. Analyzes enrollment trends over the past five years. Reports on the latest relevant news from the last three months. Key Topics Covered: Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by E7 Countries Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Clinical Trials by Sponsor Type Latest Clinical Trials News on Atopic Dermatitis (Atopic Eczema) Clinical Trial Profile Snapshots A selection of companies mentioned in this report includes, but is not limited to: Pfizer Inc Novartis AG Sanofi Regeneron Pharmaceuticals Inc LEO Foundation Eli Lilly and Co AbbVie Inc Johnson & Johnson Innovaderm Research Inc Thermo Fisher Scientific Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
